Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been impressive. Over the last four quarters, the company has beaten estimates on three occasions while being in line on another. Overall, Alexion has posted an average positive earnings surprise of 7.49% for the four trailing quarters.
Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion surpassed earnings expectations in the second quarter of 2017. Our consensus called for EPS of $1.08, and the company reported EPS of $1.31 (these figures include after tax impact of stock-based compensation expense).
Revenue: Revenues also exceeded expectations. Alexion posted revenues of $912 million, compared to our consensus estimate of $848 million.
Key Stats: Solirus sales increased 16% in the quarter to $814 million.
2017 Guidance: The company increased its revenue and earnings guidance for 2017. The company expects adjusted earnings per share to be in the range of $5.40 to $5.55 up from its previous expectation of $5.40 to $5.30. It projects revenues to be in the range of $3.45 to $3.53 billion up from its prior expectation of $3.4 to $3.5 billion. The Zacks Consensus Estimate for earnings was $4.55 per share while for sales it was $3.48 billion.
Share Price Impact: Shares rose 1.3% in pre-market trading.
More Stock News: Tech Opportunity Worth $386 Billion in 2017 From driverless cars to artifical intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future. Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Image: Bigstock
Alexion (ALXN) Tops Q2 Earnings, Sales; Shares Up
Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been impressive. Over the last four quarters, the company has beaten estimates on three occasions while being in line on another. Overall, Alexion has posted an average positive earnings surprise of 7.49% for the four trailing quarters.
Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion surpassed earnings expectations in the second quarter of 2017. Our consensus called for EPS of $1.08, and the company reported EPS of $1.31 (these figures include after tax impact of stock-based compensation expense).
Revenue: Revenues also exceeded expectations. Alexion posted revenues of $912 million, compared to our consensus estimate of $848 million.
Key Stats: Solirus sales increased 16% in the quarter to $814 million.
2017 Guidance: The company increased its revenue and earnings guidance for 2017. The company expects adjusted earnings per share to be in the range of $5.40 to $5.55 up from its previous expectation of $5.40 to $5.30. It projects revenues to be in the range of $3.45 to $3.53 billion up from its prior expectation of $3.4 to $3.5 billion. The Zacks Consensus Estimate for earnings was $4.55 per share while for sales it was $3.48 billion.
Share Price Impact: Shares rose 1.3% in pre-market trading.
Alexion Pharmaceuticals, Inc. Price and EPS Surprise
Alexion Pharmaceuticals, Inc. Price and EPS Surprise | Alexion Pharmaceuticals, Inc. Quote
More Stock News: Tech Opportunity Worth $386 Billion in 2017 From driverless cars to artifical intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future. Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>